Navigation Links
New cancer-fighting strategy focuses on signaling molecules
Date:2/24/2010

Cancer researchers studying the immune system have identified a previously unrecognized set of targets and biomarkers to battle solid tumors.

The findings center on discovery of signaling molecules that are major players in a biochemical mechanism linking certain actions of B cells to solid tumor growth. The most notable implication of the study is that a drug in use for more than decade to treat non-Hodgkin's lymphoma, which is a cancer of the B cells, might be effective against other solid tumors, says lead author Lisa Coussens, PhD, of the UCSF Helen Diller Family Comprehensive Cancer Center.

"This is paradigm shifting," emphasizes Coussens, who is a pioneer in studying the role of molecular regulation in cellular inflammation that is linked to development of cancer. "The discoveries open up our thinking to many new signaling molecules as potential therapeutic targets.''

The research is published online and in print by the scientific journal "Cancer Cell" (vol.17, issue 2, http://www.cell.com/cancer-cell/current).

"These are very significant findings because they suggest that Rituxan, a drug that we already are familiar with, could have very broad clinical implications in the treatment of some solid tumors,'' says Coussens, who also is a professor in the UCSF Department of Pathology and co-director of the Mouse Pathology Core and Program in Cancer, Immunity and Microenvironment.

The researchers found that a class of antibodies known as immunoglobulin G and the receptors to which they bind play a key role in the link between B cells and solid tumor growth. Called FcRgamma, these receptors are found on cells of the innate immune system (including mast cells, macrophages, and dendritic cells). The activation of FcRgamma plays a part in recruiting circulating immune cells to neoplastic (abnormal) tissue, which in turn enhances development of new blood vessels to feed nutrients to growing tumors and to advance progression to malignant cancer.

Most tumors are rife with activated immune cells, says Coussens, but their role in the development of cancer has been largely overlooked.

The findings may lead to more successful treatment of certain solid tumors by combining chemotherapy with drugs that can thwart cancer-promoting activities of the immune system, according to Coussens. For instance, the drug Rituxan has relatively few side effects, she adds.

As a result of the molecular discovery, Coussens is collaborating with pharmaceutical industry experts to explore new therapeutic strategies. Preclinical testing of the combination approach is underway involving therapies similar to Rituxan and chemotherapy, and initial results "look promising,'' says Coussens.

At UCSF, the Coussens lab focuses on the role of inflammatory cells and leukocyte proteases as critical regulators of skin, lung and breast cancer development. During the early development of cancer, many physiological processes occur in the vicinity of young tumor cells that are similar to processes that occur during embryonic development and to healing of wounds in adult tissue.

By studying mouse models of skin, lung and breast cancer development, the Coussens lab is identifying important molecules involved in regulating tumor-associated inflammation, angiogenesis, and cancer development. Identification of these important regulatory mechanisms reveals drug-targets that can then be used to design novel therapeutic strategies for treating cancer development in humans.

Biochemical and cellular studies during the past decade have shown that inflammation can promote the development of cancer. In addition, certain chronic inflammatory conditions, such as Crohn's disease, pancreatitis, prostatitis, asbestosis and Barrett's esophagus, are associated with an elevated cancer risk.

Discoveries over the last decade have made clear that "Chronic inflammation in the context of tumor development is associated with a poor prognosis,'' says Coussens.


'/>"/>

Contact: Elizabeth Fernandez
efernandez@pubaff.ucsf.edu
415-476-2557
University of California - San Francisco
Source:Eurekalert

Related biology news :

1. U-Iowa improves delivery of cancer-fighting molecules
2. FSU researcher using computers to hone cancer-fighting strategies
3. Researchers uncover key trigger for potent cancer-fighting marine product
4. Queens researchers propose rethinking renewable energy strategy
5. H1N1 influenza adopted novel strategy to move from birds to humans
6. Skunks strategy not just black and white
7. New strategy for mending broken hearts?
8. Strategy outlined for growing bioenergy while protecting wildlife
9. IEEE-USA President endorses national innovation strategy
10. Science Coalition commends Presidents strategy for innovation
11. New strategy for inhibiting virus replication
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... be implemented as a compact web-based "all-in-one" system solution ... the biometric fingerprint reader or the door interface with ... of modern access control systems. The minimal dimensions of ... ID readers into the building installations offer considerable freedom ...
(Date:4/14/2016)... 14, 2016 BioCatch ™, ... today announced the appointment of Eyal Goldwerger ... Goldwerger,s leadership appointment comes at a time ... the deployment of its platform at several of the ... which discerns unique cognitive and physiological factors, is a ...
Breaking Biology News(10 mins):
(Date:5/26/2016)... (PRWEB) , ... May 26, 2016 , ... ... developed by Medistem Panama Inc. at the City of Knowledge in ... tissue-derived mesenchymal stem cells in the US earlier this year following FDA approval ...
(Date:5/25/2016)... ... May 25, 2016 , ... ... delegation at BIO 2016 in San Francisco. Located at booth number 7301, representatives ... to answer questions and discuss the Thai biotechnology and life sciences sector. ...
(Date:5/25/2016)... ... ... Scientists at the University of Athens say they have evidence that the variety of ... could lead to one good one. Surviving Mesothelioma has just posted an article on ... evaluated 98 mesothelioma patients who got a second kind of drug therapy ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... diabetes, and traumatic injuries, will be accelerated by research at Worcester Polytechnic Institute ... engines of wound healing and tissue regeneration. , The novel method, developed by ...
Breaking Biology Technology: